

# Axinn Successful in Protecting Client Alvogen's Entry to Drug Market

A decorative graphic on the right side of the page features a light blue background with a white grid pattern. A white, curved, ribbon-like shape flows from the top right towards the bottom right, partially overlapping the grid.

NEWS | 1 MIN READ

March 1, 2012


Axinn obtained a favorable decision for its client, Alvogen, Inc., which allows Alvogen's valuable generic version of the antibiotic Vancocin<sup>®</sup> to remain on the market. ViroPharma, Inc. brought the case against the U.S. Food and Drug Administration to reverse the approval of three Abbreviated New Drug Applications, asking for a preliminary injunction that would have forced Alvogen's and two other pharmaceutical companies' generic versions of Vancocin off the market. U.S. District Judge Ellen Segal Huvelle ruled against ViroPharma, denying the company's bid to maintain the monopoly on Vancocin – ViroPharma's highest-selling drug – during the pendency of the case.

Within less than a week, the Axinn team successfully moved to intervene, submitted opposition papers and argued before Judge Huvelle at a hearing held on April 19. The Court denied ViroPharma's motion days later, on April 23, 2012. The Axinn team included Nick Gaglio.

The case is *ViroPharma Inc. v. Hamburg*, 12-cv-584, U.S. District Court for the District of Columbia (Washington).

## Related People

---



Nicholas E.O. Gaglio

## Related Services

---

Intellectual Property

To subscribe to our publications, [click here](#).

## Featured Insights

- American Bar Association 2025 Asia-Pacific Conference  
**SPEAKING ENGAGEMENT    ANTITRUST**
- NBA Commercial Law Section 38th Annual Corporate Counsel Conference  
**SPONSORSHIP    ANTITRUST**
- GCR Live: Law Leaders Global 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- The 32nd Annual Marketing Partner Forum  
**EVENT**
- SABA North America Corporate Counsel Retreat 2025  
**SPONSORSHIP    ANTITRUST**
- Axinn Antitrust Insight: FTC Announces Revised HSR Thresholds for 2025  
**CLIENT ALERTS    ANTITRUST**
- Four Axinn Thought Leadership Pieces Nominated for the Antitrust Writing Awards  
**AWARDS & RECOGNITIONS    ANTITRUST**

- Merger Remedies Back in Vogue Under Trump

**MEDIA MENTIONS     ANTITRUST**

- Three Takeaways from the Initial Determination at the ITC Regarding Standard Essential Patents in the 1380 Investigation

**AXINN VIEWPOINTS     INTELLECTUAL PROPERTY**

- A POSA's Motivation Is Not Required To Be the Same as the Inventor's in Evaluating Obviousness

**AXINN VIEWPOINTS     INTELLECTUAL PROPERTY**

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved